Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Cash from Operations: 2014-2025

Historic Cash from Operations for KalVista Pharmaceuticals (KALV) over the last 8 years, with Apr 2025 value amounting to -$40.4 million.

  • KalVista Pharmaceuticals' Cash from Operations fell 167.22% to -$40.4 million in Q2 2025 from the same period last year, while for Apr 2025 it was -$135.3 million, marking a year-over-year decrease of 51.66%. This contributed to the annual value of -$152.9 million for FY2025, which is 71.36% down from last year.
  • According to the latest figures from Q2 2025, KalVista Pharmaceuticals' Cash from Operations is -$40.4 million, which was down 1.82% from -$39.6 million recorded in Q4 2024.
  • KalVista Pharmaceuticals' 5-year Cash from Operations high stood at -$15.1 million for Q2 2024, and its period low was -$40.4 million during Q2 2025.
  • Its 3-year average for Cash from Operations is -$29.9 million, with a median of -$27.6 million in 2024.
  • Data for KalVista Pharmaceuticals' Cash from Operations shows a maximum YoY crashed of 167.22% (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows KalVista Pharmaceuticals' Cash from Operations stood at -$19.8 million in 2023, then crashed by 99.96% to -$39.6 million in 2024, then plummeted by 167.22% to -$40.4 million in 2025.
  • Its Cash from Operations was -$40.4 million in Q2 2025, compared to -$39.6 million in Q4 2024 and -$40.2 million in Q3 2024.